CLINICAL_TRIALS
trial_result
· 2021-06-24
Clinical Trial Update: Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation [Phase 1, Phase 2]
Summary
A phase 1/2 study of ultra-low dose subcutaneous interleukin-2 in kidney transplantation was terminated; results were posted in 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Anil K. Chandraker, MD | Conditions: Kidney Transplantation | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-06-24